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Abstract The enzyme glutaminase in brain is responsible for the
synthesis of neurotransmitter glutamate. We used the two-hybrid
genetic selection system in yeast to look for interactors of
glutaminase in human brain. We have identified two proteins
containing PDZ domains, K1-syntrophin and a glutaminase-
interacting protein, named GIP, that showed association with
human glutaminase L, as deduced from specificity test of the
two-hybrid system. The complete GIP cDNA clone has 1315
nucleotides with a 372-base open reading frame encoding a 124-
amino acids protein. Glutaminase associates with both PDZ
proteins through its C-terminal end; mutagenesis of single amino
acids revealed the sequence -ESXV as essential for the
interaction. These data suggest the possibility that PDZ
domain-containing proteins are involved in the regulation of
glutaminase in brain. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Phosphate-activated glutaminase (PAG, EC 3.5.1.2) is a
mitochondrial enzyme that catalyzes the hydrolysis of gluta-
mine to stoichiometric amounts of glutamate and ammonia.
In most mammal tissues where the enzyme is expressed, it is
involved in the generation of energy using glutamine as a
major respiratory fuel ; thus, many types of tumor cells [1],
as well as actively dividing normal cells [2], exhibit high rates
of glutamine utilization through this pathway. In the brain,
PAG also plays a key role in the synthesis of the excitatory
neurotransmitter glutamate, which indeed is used as a precur-
sor of the inhibitory neurotransmitter GABA [3].
Furthermore, the enzyme regulates the cerebral concentra-
tions of glutamine and glutamate, which are very important in
processes such as ammonia detoxi¢cation [4]. A glutamine^
glutamate intercellular cycle between neurons and glial cells
has been suggested, in such a way that the glutamate released
into the synaptic cleft is transported into the glia, converted to
glutamine by glutamine synthetase and shifted back to neu-
rons, where PAG will replenish the released glutamate stores.
The location of glutamine synthetase mostly in glial cells [5]
and that of PAG in glutamatergic ¢bers [6,7] support the
cycle, although PAG immunoreactivity is present in glial cells
too [7]. Within neurons, PAG associates with mitochondria
and synaptic vesicles [7] and also appears in a soluble form
[8] ; results from biochemical studies have also indicated the
existence of two PAG populations: a membrane-bound form
and a soluble form [9]. These results raise the possibility that a
single PAG population works to generate the glutamate
needed for metabolic purposes, whereas the second might
supply the releasable glutamate transmitter pool [7].
Molecular cloning has given additional evidence to
strengthen the view of two PAG isoenzymes being operative
in human brain: a kidney-type, K-isoform, has been cloned
from human brain [10] and a liver-type, L-isoform, has been
cloned from a human breast cancer cell line [11]. The enzymes
are the products of separate genes encoded on di¡erent chro-
mosomes and both are expressed in human brain [12]. The
expression in human brain of two PAG transcripts encoded
by di¡erent genes rises the intriguing question of which are
the physiological functions of both isozymes.
In search for additional cellular factors that may be in-
volved in the regulation of L-PAG in brain, we have used a
two-hybrid system approach. In this paper, we describe the
isolation of two potential interactors: K1-syntrophin (SNT)
and a new glutaminase-interacting protein (GIP), which con-
tain a PDZ protein recognition module [13]. Interestingly,
human brain L-PAG may have the potential to interact
with PDZ proteins because it possesses a C-terminal end,
-ESMV, which matches the consensus sequence X-Ser/Thr-
X-Val required for interaction [14], while the K-isoenzyme,
which is also expressed in human brain, lacks this motif. In
addition to the genetic analyses, direct interaction between
PAG, GIP and SNT was shown by in vitro experiments and
the essential residues of PAG involved were assessed by site-
directed mutagenesis.
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2. Materials and methods
2.1. Baits construction
The N-terminal (N-PAG) and C-terminal (C-PAG) baits were gen-
erated by inserting into the pEG202 (pLexA) vector [15] the coding
sequences for amino acid residues 1^392 and 347^602, respectively, of
the human glutaminase full-length cDNA cloned from ZR-75 breast
cancer cells [11]. The cDNA inserts were subcloned into the pEG202
vector as BamHI^XhoI fragments, generated by PCR with the follow-
ing primers: 5P-CATCAGAAAGTGGATCCTGTCCCGCCTGGG-
3P (sense primer) and 5P-GCCGCAGGAATGCTCGAGGCTGAGG-
GTGTTGC-3P (antisense primer) for N-PAG, and 5P-GCTGTGTT-
CTGTGGGGATCCCTTGTGAATCAGGC-3P (sense primer) and
5P-GTGTGGCCAGCTCGAGCTTTTTATTGAGCAGGG-3P (anti-
sense primer) for C-PAG. The two baits were sequenced in both
directions to con¢rm the rightness of the constructions.
2.2. Yeast two-hybrid screening
Two-hybrid screening for PAG-interacting proteins was carried out
as outlined by R. Brent and colleagues [16], using a Matchmaker two-
hybrid system (Clontech). The yeast strain used was EGY48 (partial
genotype MATK, his3, trp1, ura3, LexAop U6-LEU2) transformed
with the reporter plasmid p8op-LacZ. This host strain carries LEU2
and LacZ under the control of LexA operators. Screening was done
with a 57 year old human whole-brain cDNA library (Clontech)
tagged with B42 transcriptional activation domain in the pJG4-5
(pB42AD) plasmid [15], which allows galactose-dependent expression
of cDNA-encoded fusion proteins. The library was ¢rst ampli¢ed and
the ¢nal titer was 2.6U1010 cfu/ml. We ¢rst checked that the baits did
not activate the transcription of the reporter genes by themselves,
employing colonies of EGY48 transformed with URA3 LacZ reporter
plasmid. The selection strains for both baits were then transformed
with the library cDNA. Transformation was performed with a varia-
tion of the lithium acetate method [17] and the transformation e⁄-
ciency was always s 105 transformants/Wg DNA. Library transform-
ants were plated on Glu-Ura-His-Trp medium, harvested and frozen
at 370‡C in 1 ml aliquots in glycerol solution. After determining the
plating e⁄ciency (106 cfu/Wl), transformants were plated on 3Ura,
3His, 3Trp, 3Leu medium, including galactose and ra⁄nose to se-
lect for activation of the LEU2 reporter gene. The Leu+ yeast colo-
nies were further screened by ¢lter assay with 5-bromo-4-chloro-3-
indolyl L-D-galactoside (X-Gal). The Leu+ and LacZ+ clones were
restreaked and tested again for their Leu and LacZ phenotypes in a
secondary screen. After that, putative positives were also tested
against an unrelated protein fused to the DNA-binding domain, to
discard false positives that do not show speci¢city for the target pro-
tein [18]. Only those clones that ful¢lled the requirements for speci¢c-
ity on these assays were considered and sequenced on both strands
with the forward (BCO1) and reverse (BCO2) pJG4-5 sequencing
primers, using the dideoxy chain termination method [19] on an au-
tomated DNA sequencer ABI model 310 (Perkin Elmer), following
the manufacturer’s own protocol and reagents. Nucleotide and the
deduced amino acid sequences were compiled and homologies deter-
mined against the GenBank, SwissProt, Protein Identi¢cation Re-
source and Protein Data Bank using BLAST [20] and the FASTA
program of the University of Wisconsin Genetics Computer Group
(Madison, WI, USA).
2.3. Generation of glutathione S-transferase (GST) fusion proteins and
polyclonal antibodies
Amino acid sequence of residues 347^602 of the predicted C-termi-
nal region of human PAG protein (C-bait), amino acids 49^505 of the
human SNT protein [21], and the whole coding sequence of GIP were
expressed in Escherichia coli as GST fusion proteins (GST-CtPAG,
GST-SNT and GST-GIP). For construction of plasmids encoding
GST-CtPAG, an EcoRI^XhoI fragment encompassing nucleotides
1074^1909 was ligated to the EcoRI^XhoI digested pGEX-6P-1 vector
(Pharmacia). An EcoRI^XhoI restriction fragment of the SNT cDNA
clone was also ligated to the EcoRI^XhoI-digested pGEX-6P-1 vector.
For the GIP fusion construct, an EcoRI^EcoRI fragment containing
the open reading frame (ORF) of GIP (nucleotides 64^438) was li-
gated to the EcoRI-digested pGEX-6P-1 vector. Amino acid sequence
of the 602 residues of the predicted ORF region of hPAG protein was
also expressed in E. coli as fusion protein (GST-PAG) as previously
described [11]. For protein expression, these constructs and empty
pGEX-6P-1 vector were transformed into the E. coli BL21(DE3) cells
(Stratagene), and the fusion proteins were puri¢ed by using gluta-
thione-Sepharose beads, as recommended by the supplier. The puri-
¢ed recombinant proteins were used for hyperimmunization of New
Zealand white rabbits and polyclonal antibodies were generated as
described elsewhere [22].
2.4. In vitro pull-down assays
The whole coding regions of the human L-PAG and GIP cDNAs
were subcloned into the plasmid pcDNA3; the amino acid sequence
52^505 of the human SNT was subcloned into the plasmid pcDNA3,
after changing the residue E-52 for a methionine by PCR. Puri¢ed
plasmids were transcribed and translated using the TnT1-coupled
reticulocyte-lysate system (Promega) according to the manufacturer’s
instructions. In vitro translated [35S]GIP, [35S]SNT or [35S]PAG pro-
teins were incubated, for 2 h at room temperature, with puri¢ed GST-
PAG, GST-SNT or GST-GIP. Afterwards, GST fusion proteins were
pulled-down by using glutathione-Sepharose beads. The beads were
washed four times with binding bu¡er (50 mM Tris^HCl pH 8.0,
150 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol, 0.1% (w/v) Triton
X-100 and the protease inhibitors kit complete0 (Roche)) and sus-
pended in sodium dodecyl sulfate (SDS) gel loading bu¡er [23]. After
boiling for 5 min, the eluted proteins were analyzed by SDS^PAGE
and £uorography. Gels were exposed to Kodak-OMAT AR ¢lms for
3 days at 380‡C.
2.5. Mutagenesis of the C-terminal end of PAG
Point mutants were generated using the Quick Change Site-Directed
Mutagenesis kit (Stratagene) and the coding region of PAG inserted
into the pcDNA3 expression vector. The mutants V602A, M601A,
S600A and E599A were generated in the pcDNA3 vector and checked
by sequencing.
3. Results
To elucidate the existence of a signaling mechanism con-
trolling glutaminase activity in brain, we have searched for
proteins capable of interacting with PAG, using the yeast
two-hybrid approach. Initially, the N- and C-termini of the
Fig. 1. Baits employed in the two-hybrid screen and constructs used
to assess the structural requirements for PAG/GIP and PAG/SNT
interactions. (A) Human PAG protein is schematically shown on
the top, numbering besides the sequences indicates amino acids of
PAG; N-PAG, N-terminal bait; C-PAG, C-terminal bait. Point mu-
tants of the C-terminal bait tested by the two-hybrid assay for inter-
action with the PDZ clones: single amino acids were changed to
alanine at positions 602V, 601M, 600S and 599E giving mutants
V602A, M601V, S600A and E599A. (B) Schematic representation of
GST fusion constructs tested for in vitro interactions by the GST
pull-down assays.
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human PAG were subcloned into the yeast expression vector
pEG202, which was designed for yeast two-hybrid interaction
cloning [15]. Both were suitable baits because the LexA-PAG
constructs had no transcriptional activity. These portions of
PAG contained 392 and 256 amino acid residues, respectively
(Fig. 1), of the human glutaminase from ZR-75 breast cancer
cells [11]; indeed, the C-terminal 256 amino acids were iden-
tical to the predicted amino acid sequence of an EST human
brain sequence (R15359), which shares 100% identity in the
nucleotide sequence with the PAG from breast cancer cells
[11]. These constructs (pEG/C-PAG and pEG/N-PAG; Fig.
1) were used to screen a yeast expression library derived from
the cDNA of human brain. One million clones were screened,
and 37 clones were selected for pEG/C-PAG and 25 for pEG/
N-PAG in the primary screening. These clones conferred ga-
lactose-dependent phenotypes indicating protein interaction
on yeast strain EGY48, and the phenotypes segregated with
the plasmids from the cDNA library. Thus, these cDNAs
represented candidates encoding PAG-binding proteins. How-
ever, after secondary screening the number of positives de-
creased and, even more, after checking the speci¢city of the
interactions as described in the Section 2, no true positives
remained for the N-PAG construct, whereas 19 positives were
detected for the C-terminus bait.
Four cDNA clones were randomly selected from the pos-
itive pool from the human brain library and were subjected to
sequence analysis. Nucleotide sequence of hit 1 showed almost
a 100% match to the cDNA of human ubiquitin fusion-deg-
radation protein. The second hit was highly similar (96% iden-
tity in 418 nucleotides) to a guanine nucleotide-binding pro-
tein, whereas hit 4 was 100% identical to the human SNT,
namely to the N-terminal region containing a PDZ domain
Fig. 2. Nucleotide and deduced amino acid sequences of GIP. Deduced amino acids are shown under the coding sequence. Amino acid 1 is the
initiation methionine marked in bold and the stop codon is indicated by the asterisk. A polyadenylation consensus sequence is underlined. This
sequence has been submitted to GenBank under accession number AF234997.
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[21]. With regard to hit 3, its sequence was shown to be iden-
tical to both a human brain clone of unknown function (Gen-
Bank accession # U90913) [24], but adding 13 nucleotides in
the 5P-end, and to the Tax interaction protein 1, a partial
coding sequence isolated from human lymphocytes [25], ex-
tending 69 nucleotides at the 5P-end. Hit 3, thereafter referred
to as GIP, has 1315 nucleotides (Fig. 2) and contains an ORF
of 372 nucleotides that extends from the ¢rst translation con-
sensus sequence [26] of an initiation codon at position 48 to
the ¢rst termination codon at position 420. The entire cDNA
contains 47 and 896 nucleotides of 5P- and 3P-untranslated
sequences, respectively. Translation of the cDNA results in
a predicted protein of 124 amino acids with a relative Mr of
13 735 (Fig. 2).
Although the size of this cDNA agrees with estimates of the
size of the GIP mRNA obtained by Northern gel analysis
(results not shown), we wanted to assure that the whole
5P-end sequence was present in this clone. For that purpose,
the 5P-RACE (rapid ampli¢cation of cDNA ends) technique
was carried out [11] with human lymphocyte RNA and several
antisense primers £anking the 5P-end of GIP; after PCR am-
pli¢cation and Southern blot to detect the GIP-speci¢c prod-
ucts, they were cloned in pGEM-T and sequenced. However,
all the GIP clones started with the same 5P-sequence already
known and none had additional sequence upstream of the
5P-end (results not shown).
Sequence comparisons between GIP and the NCBI Gen-
Bank1 EMBL, DDBJ, PDB sequence databases showed
that it was identical to the Tax interaction protein 1 isolated
from human lymphocyte in a two-hybrid screen employing the
C-terminus of the HTLV-1 Tax oncoprotein as a bait [25]; the
only di¡erence is that the GIP sequence adds 8 amino acids at
the N-terminus. It is also noteworthy that the deduced amino
acid sequence of a putative protein of Caenorhabditis elegans
(C45g9.7, SwissProt # Q09506) containing 124 amino acids
has 63% similarity with GIP. The amino acid sequence of GIP
contains a PDZ interaction module encompassing amino acids
17^112; for this reason, apart from the Tax interaction pro-
tein and the C45g9.7 hypothetical protein, which showed the
best alignments, GIP also displays signi¢cant similarity values
with other proteins belonging to the PDZ family. Further-
more, hit 4 was the SNT protein, which also contains a
PDZ domain inserted in the ¢rst pleckstrin homology (PH)
domain [21]. In Fig. 3, the multiple alignment of representa-
tive PDZ sequences is compared with that of GIP and SNT
using the Pfam program [27].
To con¢rm the interaction between PAG and the PDZ
domains of SNT and GIP, in vitro interaction experiments
were performed by pull-down assays. GST fusion proteins
of GIP, PAG and SNT expressed in E. coli (Fig. 4A) were
immobilized on glutathione-Sepharose and incubated with
their respective interaction partners labeled with [35S]Met.
As shown in Fig. 4B, in vitro translated [35S]PAG associates
speci¢cally with both GST-GIP and GST-SNT: a strong band
was detected which indicates a selective retention of PAG to
GIP and SNT, whereas GST alone was unable to retain PAG.
Approximately 50^75% of the [35S]PAG input signal was
bound by GIP or SNT. Furthermore, the signal correspond-
Fig. 3. Multiple sequence alignment of selected PDZ domains. The alignment was done with the program Pfam 3.1 [27]. The predicted second-
ary structure included at the top of the sequences is taken from those determined in [33,34]. The sequences of GIP, SNT (SNT A1) and a
C. elegans putative protein (YQI7_CAEEL) similar to GIP are compared with six members of the class I domain of PDZ proteins (target se-
quence speci¢city: S/T-X-V/I-COO3 [36]). The name of the proteins, PDZ domain number and the domain limits are indicated at the beginning
of the sequences; database accession codes follow the alignment. Essential residues for interaction with the peptide ligand are shown in gray;
dots represent insertions/deletions.
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ing to the [35S]PAG bound decreases to 20^25% of the control
values when a competition assay was done in the presence of a
four molar excess of cold PAG (results not shown). Similar
results were obtained by using GST-PAG to interact with
[35S]GIP or [35S]SNT (data not shown). Thus, the binding
of PAG/GIP and PAG/SNT seem highly speci¢c interac-
tions.
Since both GIP and SNT have a PDZ interaction domain
and PAG has a C-terminus which conforms to the consensus
PDZ recognition sequence, it is therefore most likely that the
interaction occurs via PDZ modules. Therefore, we then
tested whether the PAG C-terminal domain is involved in
the interaction; concretely, we analyzed the contribution of
individual residues. The analysis was performed with the two-
hybrid assay in yeast by comparing the interaction of the
C-terminal PAG bait protein with that of mutated forms,
where residues at positions 0, 31, 32 and 33 were changed
to alanine, giving mutants V602A, M601A, S600A and
E599A. In Fig. 5, the results are monitored following the
L-galactosidase assay in the plate, which indicates whether
the interaction occurs or not and the strength of the interac-
tion. As can be seen in Fig. 5 (right plate), the mutants V602A
and S600A of PAG completely abolish the interaction with
GIP, the mutant M601A was without e¡ect, whereas a lower
level of interaction was seen with the mutant E599A. Some
di¡erent results were obtained with the PDZ domain of SNT
(left plate): the glutamate at position 33 of PAG was essen-
tial for the interaction and the serine at 32 was considerably
less critical than for GIP. The last valine (V602) was again
essential to maintain the SNT-PAG interaction, as in the case
of the pair GIP-PAG. Thus, there is strong evidence that the
C-terminal amino acid residues of PAG are key determinants
of the interaction.
Fig. 4. GST pull-down assays. (A) GST-PAG, GST-GIP and GST-
SNT were expressed in E. coli and puri¢ed by glutathione-Sephar-
ose. The a⁄nity-puri¢ed GST proteins were analyzed by SDS^
PAGE and stained with Coomassie blue R-250. Standard molecular
weight markers are in lane STD, from top to bottom: phosphory-
lase b (94 kDa), BSA (67 kDa) and ovalbumin (43 kDa). (B) GST-
PAG immobilized on glutathione-Sepharose beads was incubated
with [35S]Met-labeled, in vitro translated GIP or SNT. Bound pro-
teins were analyzed by SDS^PAGE and visualized by autoradiogra-
phy. Control lanes with only recombinant GST (without PAG) are
also shown.
Fig. 5. Analysis of the interaction between PAG mutants and the PDZ clones GIP and SNT using a solid culture L-galactosidase assay. Yeasts
were cotransformed with the cDNA of wild-type or point mutants PAG and the cDNA of SNT or GIP. Transformants were plated on Gal/
Raf Ura-His-Trp- plates containing X-Gal; the interaction between PAG and SNT or GIP was revealed by the intensity of the blue color de-
veloped after reporter gene activation, while white colonies re£ect lack of interaction. Control glucose Ura-His-Trp- X-Gal plates and Gal/Raf
Ura-His-Trp-Leu- plates were used to con¢rm the interactions (results not shown). Interaction PAG/SNT, left plate; interaction PAG/GIP,
right plate; PAG point mutants are indicated onto the corresponding section of the plate.
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4. Discussion
In this study we have shown that the human L isoenzyme of
PAG has the potential to interact with two members of the
PDZ domain-containing anchoring proteins through its C-ter-
minal motif of ESMV. Furthermore, we describe the isolation
of a full-length cDNA clone encoding a novel member of the
PDZ family, GIP, while the second interactor isolated, SNT,
also contains a PDZ domain. Both cDNAs were isolated from
human brain and, interestingly, two isoenzymes of glutami-
nase are expressed in this tissue: the kidney-type K-PAG and
the liver-type L-PAG [10^12].
We designed the C-bait of PAG after complete sequencing
of a human brain partial cDNA clone (GenBank accession #
AF110331), which has almost 100% identity with the L-PAG
cDNA of ZR-75 breast cancer cells, encompassing nucleotides
1070^2408; that is, the C-terminal half and all the 3P-UTR
region [11]. Moreover, during the course of this work, a full
cDNA sequence corresponding to the L-PAG enzyme has
been cloned from human brain and deposited in the database
(GenBank accession # AF223944). The protein has a 96%
overall identity with our sequence from breast tumor cells,
having only two di¡erences ^ A560V and L581P ^ in the
last C-terminal 256 amino acids used as bait in the two-hybrid
screen. Although these changes do not alter the C-termini
PDZ consensus sequence of L-PAG, it should be noted that
they only appear in the sequence AF223944, because all the
putative glutaminase EST from human and mouse, as well as
the rat liver enzyme [28], have A and L in those positions in
agreement with the breast cancer sequence.
Whereas no real positive was obtained with the ¢rst 392
amino acids of PAG (N-bait), the two-hybrid screen with
the last 256 amino acids (C-bait) led to the isolation of several
positives, and two of them were related by the presence of one
PDZ domain: SNT and the new protein GIP. The sequence of
GIP is mainly composed of a single PDZ module, which is
unusual in this family of proteins; a hypothetical protein
C45g9.7 of 124 amino acids in C. elegans (SwissProt #
Q09506) shares 63% of similarity over 117 amino acids;
thus, this genomic sequence would constitute the homolog
of GIP in C. elegans. Furthermore, this hypothetical protein
and GIP represent until now the shortest members of the PDZ
family. Syntrophins are a family of intracellular peripheral
membrane proteins expressed in skeletal muscle, heart, brain
and some other human tissues [21]. SNT has other sequence
motifs, apart from the PDZ domain: two PH domains and
one syntrophin unique (SU) domain. The clone of SNT iso-
lated in this study was almost complete, containing all the
domains except half of the ¢rst PH domain, because the se-
quence lacks the ¢rst 48 amino acids. In brain, the PDZ
domain of SNT is known to bind to protein kinases [29]
and to the neuronal nitric oxide synthase [30] ; the interactions
have been postulated as a mechanism for selective targeting of
these proteins to unique subcellular sites in brain. From our
results, it can also be proposed that SNT might contribute to
determining the subcellular localization of PAG in certain
regions of the brain, thereby creating a mechanism to regulate
PAG activity.
The overall amino acid distribution for the PDZ domains
does not show many conserved positions, a fact that derives
from the large sequence divergence of this fold family [31].
However, techniques of sequence analysis [31,32] and nuclear
magnetic resonance and X-ray studies of several PDZ proteins
[33,34] have supported evidence about the conserved residues
of the PDZ modules and their roles in the binding of the
target peptide. As shown in Fig. 3, the PDZ domains of
GIP and SNT share the essential residues deduced from stud-
ies of structural requirements of the PDZ modules [33,34]. For
example, the hydrophobic amino acid residues forming the
pocket which accommodate the side-chain of the C-terminal
valine (Leu29-Phe31-Ile33-Leu97 for GIP and Leu98-Ile100-
Ile102-Leu155 for SNT). A key amino acid is also the KB2
histidine (second residue of the helix KB, nomenclature as
outlined in [33]) which is known to play a critical role in
PDZ domain target recognition speci¢city through formation
of a strong hydrogen bond between NO of His and the hydrox-
yl group of a Ser/Thr residue at position 32 [33,35]. Another
structural feature shared by GIP and the second PDZ domain
of SP90 (PSD-95 protein) is an unusually large loop connect-
ing LB and LC strands: 13 amino acids in SP90 and 20 amino
acids in GIP (Fig. 3). A role in determining the target-binding
speci¢city has been postulated for this loop in the PSD-95
PDZ2 domain [34], which is also longer than normal in the
C. elegans PDZ protein (Fig. 3).
The interaction between PAG and the PDZ domains of
GIP and SNT is supported by clear experimental evidence.
It was observed by the two-hybrid assay and also by GST
pull-down assays. PDZ domains have been divided into two
major groups on the basis of the amino acid selected at the
32 position of the target peptide: group 1 interacts with pep-
tides containing hydroxyl groups (Ser, Thr or Tyr) at position
32, whereas group 2 selects peptides with hydrophobic amino
acids at 32, usually Phe [36]. The PDZ domains of both GIP
and SNT belong to group 1, which also include the three PDZ
domains of the human SP90 [14,33,34], the third and ¢fth
PDZ domains of the phosphotyrosine phosphatase (PTPbas-
3 and PTPbas-5) [36], and the three PDZ domains of murine
hDlg (mDlg) [36]. It is interesting to note that in a previous
two-hybrid screen employing a cDNA library from human
lymphocytes and the Tax oncoprotein as bait, a cDNA clone
of GIP and a truncated cDNA clone of L1-syntrophin were
isolated too [25]. L1-Syntrophin is highly related to SNT and
shares a similar domain organization [37]. The C-terminus of
Tax oncoprotein, ETEV, is very similar to that of PAG, con-
taining the three essential amino acids: the carboxy-terminal
valine, threonine at position 32 and glutamate at 33.
Finally, the experiments of point mutations also reinforced
the speci¢city of the interactions PAG/GIP and PAG/SNT,
giving additional information regarding the key residues in-
volved. The C-terminal valine was revealed as absolutely es-
sential for both interactions, while the Met at 31 was irrele-
vant, in agreement with previous reports which consider
selection at this position not being a strict requirement [34].
The other C-termini positions with the highest selection were
Ser at 32 for GIP and Glu at 33 for SNT. Although being
important to maintain the interaction, a lower degree of se-
lectivity was shown by position 33 for GIP and 32 for SNT.
The LB2 Ser residue and LC4 Thr/Ser residues in GIP and
SNT seem to be key determinants to select Glu at the 33
position, via hydrogen bond formation [33].
The ¢ndings reported in this work suggest that PDZ pro-
teins, which are known to direct the target proteins into func-
tional signaling networks, can interact with L-PAG; such in-
teraction may account for a regulated mechanism of
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glutamate synthesis, accumulation, or release in human brain.
It is noteworthy that two isoenzymes of PAG are expressed in
human brain; the need for two genes and two PAGs to sup-
port the single process of glutamate synthesis is unexplained,
and identifying the role of each PAG is an important factor in
understanding glutamate-mediated neurotransmission. Inter-
estingly, the K-PAG, unlike L-PAG, does not have a PDZ-
binding domain and thus PDZ proteins could be important
for determining di¡erential cellular or subcellular localization
of the two PAG isoforms in the CNS. Further analysis is
required to understand the physiological signi¢cance of the
interaction between L-PAG and PDZ proteins in human
brain.
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